Article (Scientific journals)
The ADAMTS2 metalloproteinase inhibits tumor growth by regulating the innate immune system.
Joannes, Loïc; Dupont, Laura; Stock, Louis et al.
2025In Cancer Cell International, 25 (1), p. 229
Peer Reviewed verified by ORBi
 

Files


Full Text
Joannes Cancer Cell Int 2025.pdf
Publisher postprint (6.65 MB) Creative Commons License - Attribution
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
ADAMTS; IMMUNITY; Tumor micro-environment; Oncology; Genetics; Cancer Research
Abstract :
[en] [en] BACKGROUND: ADAMTS2 is a metalloproteinase known to be implicated in collagen maturation and regulation of (lymph)angiogenesis. As these properties are likely to alter tumor progression, we aimed to assess the overall impact of ADAMTS2 on cancer development. METHODS AND RESULTS: Using publicly available human cancer datasets, we found that high expression of ADAMTS2 in primary tumors is associated with poor prognosis across various cancer types. Similar analyses were repeated, but this time using the ratio of ADAMTS2 on COL1A1 expression to take into account potential biases due to the involvement of ADAMTS2 in collagen fibril formation. Remarkably, these data indicate that patients with a high ADAMTS2/COL1A1 ratio exhibit an improved overall survival rate, suggesting that ADAMTS2 may inhibit cancer progression by a mechanism independent of collagen accumulation. This hypothesis was evaluated in vivo using ADAMTS2-KO mice and different tumor models characterized by the absence or presence of tumor collagen accumulation, as in MMTV-PyMT mice which develop spontaneous desmoplastic mammary tumors. In all the models, the growth of primary tumors was strongly increased in ADAMTS2-KO mice versus their wild type counterparts, confirming that ADAMTS2 displays anti-tumor properties. In stark contrast, the spread of lung metastases from mammary tumors was virtually prevented in ADAMTS2-KO mice, showing a dual role of ADAMTS2, either beneficial or detrimental, at different stages of cancer progression. Additional investigations, notably by FACS and single cell sequencing, showed that the effect of ADAMTS2 on primary tumors does not result from a direct effect on cancer cells, but rather from modifications in the intratumor innate immune system which becomes more immunosuppressive in the absence of ADAMTS2. CONCLUSION: We have shown that ADAMTS2 suppresses tumor growth by inhibiting the progressive establishment of an immunosuppressive microenvironment. Conversely, its presence allows efficient formation of lung metastases. These data identify ADAMTS2 as a cancer regulator with antagonistic functions, limiting initial progression but promoting efficient metastatic dissemination.
Disciplines :
Oncology
Author, co-author :
Joannes, Loïc  ;  Université de Liège - ULiège > GIGA
Dupont, Laura ;  Université de Liège - ULiège > GIGA > GIGA Cancer - Connective Tissue Biology
Stock, Louis ;  Université de Liège - ULiège > GIGA
Arpigny, Esther ;  Université de Liège - ULiège > GIGA
Hubert, Pascale  ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
Ancion, Marie ;  Université de Liège - ULiège > GIGA > GIGA Cancer - Experimental Pathology
Luyckx, Margaux ;  Université de Liège - ULiège > GIGA > GIGA Cancer - Experimental Pathology
Abinet, Joan ;  Université de Liège - ULiège > GIGA
Peng, Wen  ;  Université de Liège - ULiège > GIGA
Calaldo, Didier;  Laboratory of Tumor and Development Biology, GIGA Institute, University of Liège, Liège, Belgium ; Liege University Hospital (CHU Liege), Liege, Belgium
Noël, Agnès  ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire
Marichal, Thomas  ;  Université de Liège - ULiège > GIGA > GIGA Immunobiology - Immunophysiology ; Walloon Excellence in Life Sciences and Biotechnology (WELBIO) Department, WEL Research Institute, Wavre, 1300, Belgium
Herfs, Michael ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques
Deroanne, Christophe ;  Université de Liège - ULiège > GIGA > GIGA Cancer - Connective Tissue Biology
Colige, Alain ;  Université de Liège - ULiège > GIGA > GIGA Cancer - Connective Tissue Biology
More authors (5 more) Less
Language :
English
Title :
The ADAMTS2 metalloproteinase inhibits tumor growth by regulating the innate immune system.
Publication date :
23 June 2025
Journal title :
Cancer Cell International
eISSN :
1475-2867
Publisher :
BioMed Central Ltd, England
Volume :
25
Issue :
1
Pages :
229
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
Télévie
F.R.S.-FNRS - Fonds de la Recherche Scientifique
Fondation contre le Cancer
WELBIO - Walloon Excellence in Life Sciences and Biotechnology
ERC - European Research Council
Fonds Baillet Latour
Fondation Léon Fredericq
ULiège FSR - Université de Liège. Fonds spéciaux pour la recherche
Funding text :
AC is \u201CSenior Research Associate\u201D, CD and MH are \u201CResearch Associate\u201D of the Fund for Scientific Research \u2014 National Fund for Scientific Research (FRS-FNRS). This work was supported by grants from T\u00E9l\u00E9vie (TLV7.65.12.2), FRS-FNRS (FC96394, J.0034.24 and PDR2024), the Foundation against Cancer (Grant 2024 \u2212 187), the \u201CFonds sp\u00E9ciaux de la Recherche\u201D (University of Li\u00E8ge), the \u201CFondation Hospitalo-Universitaire L\u00E9on Fredericq\u201D (University of Li\u00E8ge), the \u201CWalloon Region\u201D through the \u201CFRFS-WELBIO\u201D strategic research program. T.M. is supported by a FRFS-Welbio Advanced Grant (WELBIO-CR-2022\u00A0A-10), by an ERC Starting Grant ERC StG 2018 (IM-ID: 801823) and by the Baillet Latour Biomedical Fund. This work was also supported in part by the FNRS [CDR J.0088.21 (MH), AMG-ONCO P.A002.23 (MH)], the University of Liege [Cr\u00E9dits Sectoriels de Recherche en Sciences de la Sant\u00E9 2021\u20132023 (MH)], the T\u00E9l\u00E9vie [PDR Televie 7.8505.22 (MH)] and the Leon Fredericq Foundation.AC is \u201CSenior Research Associate\u201D, CD and MH are \u201CResearch Associate\u201D of the Fund for Scientific Research \u2014 National Fund for Scientific Research (FRS-FNRS). This work was supported by grants from T\u00E9l\u00E9vie (TLV7.65.12.2), FRS-FNRS (FC96394, J.0034.24 and PDR2024), the Foundation against Cancer (Grant 2024\u2009\u2212\u2009187), the \u201CFonds sp\u00E9ciaux de la Recherche\u201D (University of Li\u00E8ge), the \u201CFondation Hospitalo-Universitaire L\u00E9on Fredericq\u201D (University of Li\u00E8ge), the \u201CWalloon Region\u201D through the \u201CFRFS-WELBIO\u201D strategic research program. T.M. is supported by a FRFS-Welbio Advanced Grant (WELBIO-CR-2022 A-10), by an ERC Starting Grant ERC StG 2018 (IM-ID: 801823) and by the Baillet Latour Biomedical Fund. This work was also supported in part by the FNRS [CDR J.0088.21 (MH), AMG-ONCO P.A002.23 (MH)], the University of Liege [Cr\u00E9dits Sectoriels de Recherche en Sciences de la Sant\u00E9 2021\u20132023 (MH)], the T\u00E9l\u00E9vie [PDR Televie 7.8505.22 (MH)] and the Leon Fredericq Foundation.
Available on ORBi :
since 07 July 2025

Statistics


Number of views
91 (6 by ULiège)
Number of downloads
29 (3 by ULiège)

Scopus citations®
 
0
Scopus citations®
without self-citations
0
OpenCitations
 
0
OpenAlex citations
 
0

Bibliography


Similar publications



Contact ORBi